New vaccine trial aims to shield teens and adults from whooping cough
NCT ID NCT07492303
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new combination vaccine that protects against whooping cough, diphtheria, and tetanus (Tdap) in people aged 10 and older. Researchers want to see if different doses are safe and trigger an immune response. The study involves 96 volunteers and compares the vaccine to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tdap vaccine (acellular pertussis, diphtheria, tetanus combined)
- What this could lead to
- If successful, this could lead to a new, safe vaccine option to protect adolescents and adults from whooping cough, diphtheria, and tetanus.
- What could go wrong
- This is an early Phase 1 trial with only 96 participants, so it's too soon to know if the vaccine works. The main goal is safety, and unexpected side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIPHTHERIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new vaccine shield older kids and adults from three deadly infections?
- Can a Five-Part vaccine bolster protection against three serious infections?
- Can a single shot keep tetanus at bay?
- Will a single DTP vaccine dose protect for a decade? study tracks antibodies
- Can a new tetanus shot offer stronger protection?
- Are adults in beijing still protected against tetanus? a study investigates